IL4R and Alzheimer disease: Dupilumab, a monoclonal antibody targeting the interleukin‐4 receptor alpha (IL‐4Rα) subunit, has emerged as a promising therapeutic option for moderate‐to‐severe AD.4, 5, 6, 7